TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cemented Versus Uncemented Fixation of Humeral Components in Total Shoulder Arthroplasty for Osteoarthritis of the Shoulder
Brief Summary: The purpose of the study is to investigate the fixation of the humeral component in total shoulder arthroplasty for primary osteoarthritis of the glenohumeral joint.Our hypothesis is that uncemented fixation of the humerus will result in better disease-specific quality of life, decreased incidence of radiographic loosening, decrease operative time and no increase in complications.


Options:
A: Arm Label: 0 degrees humeral component version; Type: EXPERIMENTAL; Interventions: Device: 0 degrees humeral component version | Arm Label: 30 degrees humeral component retroversion; Type: EXPERIMENTAL; Interventions: Device: 30 degrees humeral component retroversion | Intervention Type: DEVICE; Name: 0 degrees humeral component version; Assigned to Arm(s): 0 degrees humeral component version | Intervention Type: DEVICE; Name: 30 degrees humeral component retroversion; Assigned to Arm(s): 30 degrees humeral component retroversion
B: Intervention Type: PROCEDURE; Name: Cemented Humeral Stem; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Uncemented Humeral Stem; Assigned to Arm(s): N/A
C: Arm Label: Anatomic TSA using SOC Instrumentation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anatomic Total Shoulder Arthroplasty | Arm Label: Anatomic TSA Using IRI Instrumentation; Type: EXPERIMENTAL; Interventions: Device: Anatomic TSA using IRI Instrumentation, Procedure: Anatomic Total Shoulder Arthroplasty | Intervention Type: DEVICE; Name: Anatomic TSA using IRI Instrumentation; Assigned to Arm(s): Anatomic TSA Using IRI Instrumentation | Intervention Type: PROCEDURE; Name: Anatomic Total Shoulder Arthroplasty; Assigned to Arm(s): Anatomic TSA Using IRI Instrumentation, Anatomic TSA using SOC Instrumentation
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Copeland or Global CAP resurfacing prosthesis | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Copeland or Global CAP resurfacing prosthesis | Intervention Type: PROCEDURE; Name: Copeland or Global CAP resurfacing prosthesis; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Arthroscopic Surgery Versus Non-surgical Treatment of Osteoarthritis of the Knee
Brief Summary: The purpose of this trial is to evaluate the effectiveness of arthroscopy (lavage and debridement) in conjunction with the best available non-surgical treatment versus the best available non-surgical treatment alone (medication, health education and physical therapy) in patients with osteoarthritis of the knee.


Options:
A: Arm Label: Arthroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic meniscal repair or resection | Arm Label: Exercise and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and education | Intervention Type: PROCEDURE; Name: Arthroscopic meniscal repair or resection; Assigned to Arm(s): Arthroscopy | Intervention Type: BEHAVIORAL; Name: Exercise and education; Assigned to Arm(s): Exercise and Education
B: Arm Label: Arthroscopic partial meniscectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic partial meniscectomy | Arm Label: Arthroscopy (diagnostic); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopy (diagnostic) | Intervention Type: PROCEDURE; Name: Arthroscopic partial meniscectomy; Assigned to Arm(s): Arthroscopic partial meniscectomy | Intervention Type: PROCEDURE; Name: Arthroscopy (diagnostic); Assigned to Arm(s): Arthroscopy (diagnostic)
C: Arm Label: Arthroscopic partial meniscectomy; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial menisectomy | Arm Label: Exercise Therapy; Type: EXPERIMENTAL; Interventions: Other: Supervised neuromuscular and strength training | Intervention Type: PROCEDURE; Name: Arthroscopic partial menisectomy; Assigned to Arm(s): Arthroscopic partial meniscectomy | Intervention Type: OTHER; Name: Supervised neuromuscular and strength training; Assigned to Arm(s): Exercise Therapy
D: Arm Label: Arthroscopy plus Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopy plus Medical Management, Other: Medical Management | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Arthroscopy plus Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Arthroscopic Surgery Versus Non-surgical Treatment of Osteoarthritis of the Knee
Brief Summary: The purpose of this trial is to evaluate the effectiveness of arthroscopy (lavage and debridement) in conjunction with the best available non-surgical treatment versus the best available non-surgical treatment alone (medication, health education and physical therapy) in patients with osteoarthritis of the knee.


Options:
A: Arm Label: Surgical; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial menisectomy, Other: Postoperative rehabilitative physical therapy | Arm Label: Nonoperative; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard physical therapy | Intervention Type: PROCEDURE; Name: Arthroscopic partial menisectomy; Assigned to Arm(s): Surgical | Intervention Type: OTHER; Name: Standard physical therapy; Assigned to Arm(s): Nonoperative | Intervention Type: OTHER; Name: Postoperative rehabilitative physical therapy; Assigned to Arm(s): Surgical
B: Arm Label: APM group; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial meniscectomy | Arm Label: Sham group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: PROCEDURE; Name: Arthroscopic partial meniscectomy; Assigned to Arm(s): APM group | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham group
C: Arm Label: Arthroscopy plus Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopy plus Medical Management, Other: Medical Management | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Arthroscopy plus Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management
D: Arm Label: Arthroscopic microfracture (MF); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic microfracture (MF) | Arm Label: Arthroscopic debridement (AD); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopic debridement (AD) | Intervention Type: PROCEDURE; Name: Arthroscopic microfracture (MF); Assigned to Arm(s): Arthroscopic microfracture (MF) | Intervention Type: PROCEDURE; Name: Arthroscopic debridement (AD); Assigned to Arm(s): Arthroscopic debridement (AD)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212)
Brief Summary: Herpes virus type 2 (HSV-2) infection - as a cofactor of human immunodeficiency virus (HIV) transmission - can be targeted by anti-herpetic specific drugs, either as a continuous prophylactic treatment during its asymptomatic shedding phase, or as an episodic treatment during clinically-apparent genital ulcerations. The main objective of this trial will be to demonstrate that acyclovir treatment given during clinical episodes (primary infection or recurrences) can reduce genital shedding of HIV, thereby contributing to a reduction of HIV infectiousness of dually infected individuals (HIV+/HSV+).


Options:
A: Arm Label: valacyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valacyclovir | Arm Label: high dose valacyclovir; Type: EXPERIMENTAL; Interventions: Drug: valacyclovir | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): high dose valacyclovir | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): valacyclovir
B: Arm Label: Arm 1 Male circumcision; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Male circumcision | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: Procedure: Male circumcision | Intervention Type: PROCEDURE; Name: Male circumcision; Assigned to Arm(s): Arm 1 Male circumcision, Arm 2
C: Intervention Type: DRUG; Name: Acyclovir (ACV); Assigned to Arm(s): N/A
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Valacyclovir, Drug: Matching Placebo | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): I

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212)
Brief Summary: Herpes virus type 2 (HSV-2) infection - as a cofactor of human immunodeficiency virus (HIV) transmission - can be targeted by anti-herpetic specific drugs, either as a continuous prophylactic treatment during its asymptomatic shedding phase, or as an episodic treatment during clinically-apparent genital ulcerations. The main objective of this trial will be to demonstrate that acyclovir treatment given during clinical episodes (primary infection or recurrences) can reduce genital shedding of HIV, thereby contributing to a reduction of HIV infectiousness of dually infected individuals (HIV+/HSV+).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: valacyclovir | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Valacyclovir, Drug: Matching Placebo | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): I
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Benzathine Penicillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benzathine Penicillin, Drug: Doxycycline | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Benzathine Penicillin; Assigned to Arm(s): Benzathine Penicillin | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Benzathine Penicillin
D: Intervention Type: DRUG; Name: Acyclovir (ACV); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of an HSV2 Genital Herpes Suppressive Treatment on HIV and HSV2 Genital Shedding Among Co-Infected Patients Receiving or Not Antiretroviral Drugs
Brief Summary: Genital herpes is a long-life sexually transmitted diseases which infects a large proportion of women in Africa. Its clinical symptoms are painful sores on the genitals, which heals after a few days. HIV infection can worsen genital herpes. In turn, it is possible that genital herpes increases the quantity of HIV secreted at the genital level in women infected by the 2 viruses. This study is dedicated to verify this hypothesis.


Options:
A: Arm Label: Arm 1 Male circumcision; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Male circumcision | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: Procedure: Male circumcision | Intervention Type: PROCEDURE; Name: Male circumcision; Assigned to Arm(s): Arm 1 Male circumcision, Arm 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acyclovir | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Acyclovir placebo | Intervention Type: DRUG; Name: Acyclovir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Acyclovir placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Acyclovir (ACV); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.
Brief Summary: Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of alglucosidase alfa treatment in patients with late-onset Pompe disease as compared to placebo.


Options:
A: Arm Label: alglucosidase alfa; Type: ACTIVE_COMPARATOR; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): alglucosidase alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: avalglucosidase alfa (GZ402666); Type: EXPERIMENTAL; Interventions: Drug: Avalglucosidase alfa (GZ402666) | Arm Label: alglucosidase alfa (GZ419829); Type: ACTIVE_COMPARATOR; Interventions: Drug: Alglucosidase alfa (GZ419829) | Intervention Type: DRUG; Name: Avalglucosidase alfa (GZ402666); Assigned to Arm(s): avalglucosidase alfa (GZ402666) | Intervention Type: DRUG; Name: Alglucosidase alfa (GZ419829); Assigned to Arm(s): alglucosidase alfa (GZ419829)
C: Arm Label: Clenbuterol; Type: EXPERIMENTAL; Interventions: Drug: Clenbuterol | Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Clenbuterol; Assigned to Arm(s): Clenbuterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator
D: Arm Label: Alglucosidase Alfa/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): Alglucosidase Alfa/Alglucosidase Alfa, Placebo/Alglucosidase Alfa

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electronic Communications and Home Blood Pressure Monitoring
Brief Summary: The control of blood pressure (BP) for patients with hypertension on medications has been elusive, despite the availability of evidence-based nationally recognized guidelines for treatment and 30 years of research addressing this. At present, less than 50% of patients with known hypertension are adequately controlled. If BP control could be improved, significant decreases in cardiovascular morbidity and mortality would occur.

The purpose of this study is to conduct a randomized controlled trial of the effectiveness of the provision of home blood pressure measurement and electronic communications (secure messaging to health care providers) to improve hypertension control.


Options:
A: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Home BP;secure messaging;pharmaceutical care;; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
D: Arm Label: Pharmaceutical Education; Type: EXPERIMENTAL; Interventions: Behavioral: Education interventional | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Education interventional; Assigned to Arm(s): Pharmaceutical Education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electronic Communications and Home Blood Pressure Monitoring
Brief Summary: The control of blood pressure (BP) for patients with hypertension on medications has been elusive, despite the availability of evidence-based nationally recognized guidelines for treatment and 30 years of research addressing this. At present, less than 50% of patients with known hypertension are adequately controlled. If BP control could be improved, significant decreases in cardiovascular morbidity and mortality would occur.

The purpose of this study is to conduct a randomized controlled trial of the effectiveness of the provision of home blood pressure measurement and electronic communications (secure messaging to health care providers) to improve hypertension control.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Blood Pressure Monitoring Group; Type: EXPERIMENTAL; Interventions: Behavioral: Home Blood Pressure Monitoring | Intervention Type: BEHAVIORAL; Name: Home Blood Pressure Monitoring; Assigned to Arm(s): Home Blood Pressure Monitoring Group
B: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management
D: Intervention Type: BEHAVIORAL; Name: Home BP;secure messaging;pharmaceutical care;; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.
Brief Summary: The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.


Options:
A: Arm Label: Symbicort then Formoterol then Placebo; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Arm Label: Formoterol then Symbicort then Placebo; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Arm Label: Placebo then Formoterol then Symbicort; Type: PLACEBO_COMPARATOR; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Intervention Type: DRUG; Name: budesonide/formoterol Turbuhaler 320/9µg; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo | Intervention Type: DRUG; Name: formoterol Turbuhaler 9µg; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo
B: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1
D: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.
Brief Summary: The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.


Options:
A: Arm Label: F 4.5 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 4.5mg | Arm Label: F 9.0 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 9 mg | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Turbuhaler® placebo | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 4.5mg; Assigned to Arm(s): F 4.5 bid | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 9 mg; Assigned to Arm(s): F 9.0 bid | Intervention Type: DRUG; Name: Turbuhaler® placebo; Assigned to Arm(s): PBO
B: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Salbutamol/albuterol | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237, Drug: Salbutamol/albuterol | Arm Label: open-label tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): open-label tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): NVA237, QVA149, open-label tiotropium
C: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
D: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo

Answer: C